Technologies related to NIAID

Title
Chlamydial Vaccine Technologies
Ref: E-031-2006-0 | Updated: Mar 28, 2018
Protein Nanoparticles for Antigen Display in Vaccines
Ref: E-005-2017/0 | Updated: Mar 9, 2018
Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging
Ref: E-168-2016/0 | Updated: Jan 19, 2018
Compositions and Methods for Blocking Transmission of Plasmodium
Ref: E-294-2016/0 | Updated: Jan 11, 2018
Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
Ref: E-738-2013/0 | Updated: Dec 15, 2017
Plasmids Encoding and Producing Anthrax Toxin Proteins
Ref: E-059-2008/0 | Updated: Dec 6, 2017
Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs
Ref: E-283-2001/0 | Updated: Dec 4, 2017
Mouse CCR1 cDNA
Ref: B-012-1998/0 | Updated: Dec 4, 2017
Human CCR3 cDNA
Ref: B-009-1998/0 | Updated: Dec 4, 2017
Human CCR2 cDNA
Ref: B-008-1998/0 | Updated: Dec 4, 2017
Plasmid pNL4-3, HIV Clone For Easy Mutational Changes
Ref: B-005-1999/0 | Updated: Dec 4, 2017
Human fMLP Receptor / FPR cDNA
Ref: B-007-1995/0 | Updated: Dec 4, 2017
Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA
Ref: B-005-1995/0 | Updated: Dec 4, 2017
CXCR1 - Human IL-8 Receptor cDNA
Ref: B-004-1995/0 | Updated: Dec 4, 2017
Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA
Ref: B-037-1995/6 | Updated: Dec 4, 2017
Human FPRL1 / FPR2 cDNA
Ref: B-008-1995/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody
Ref: B-004-1991/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody
Ref: B-004-1991/1 | Updated: Dec 4, 2017
Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5
Ref: E-296-2007/0 | Updated: Dec 4, 2017
Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex
Ref: B-021-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex
Ref: B-020-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody
Ref: B-006-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Ref: B-059-1994/2 | Updated: Dec 4, 2017
Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80
Ref: B-059-1994/1 | Updated: Dec 4, 2017
Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Ref: B-059-1994/0 | Updated: Dec 4, 2017
Regulator of G Protein Signaling (RGS13) Knock-Out Mouse
Ref: E-181-2008/0 | Updated: Dec 4, 2017
Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody
Ref: B-004-1991/2 | Updated: Dec 4, 2017
Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody
Ref: B-004-1991/3 | Updated: Dec 4, 2017
Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody
Ref: B-004-1991/4 | Updated: Dec 4, 2017
Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody
Ref: B-004-1991/5 | Updated: Dec 4, 2017
Neutralizing Antibodies to Influenza HA and Their Use and Identification
Ref: E-061-2016/0 | Updated: Oct 31, 2017
Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein
Ref: E-300-2009/0 | Updated: Oct 10, 2017
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-120-2013/0 | Updated: Oct 2, 2017
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-256-2015/0 | Updated: Feb 27, 2018
Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody
Ref: E-101-2013/0 | Updated: Sep 5, 2017
Compounds That Treat Malaria and Prevent Malaria Transmission
Ref: E-283-2009/0 | Updated: Jul 18, 2017
Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
Ref: E-059-2004/0 | Updated: Jul 6, 2017
Methods for Treating Cerebral Edema and Restoring Blood-Brain Barrier Integrity
Ref: E-202-2015/0 | Updated: Jun 14, 2017
Products for Treatment and Prevention of Ebola Zaire Disease
Ref: E-045-2015/0 | Updated: May 22, 2017
A Second CD4-binding Region of HIV-1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development
Ref: E-230-2015/0 | Updated: May 3, 2017
Live Attenuated Zika Virus Vaccine
Ref: E-118-2016/0 | Updated: May 1, 2017
Compositions and Methods for Detecting Loa loa
Ref: E-140-2015/0 | Updated: Apr 20, 2017
A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development
Ref: E-114-2017/0 | Updated: Apr 10, 2017
N6, A Novel, Broad, Highly Potent HIV-specific Antibody
Ref: E-131-2015/0 | Updated: Mar 15, 2017
AMA1-RON2 Complex-Based Vaccine Against Malaria
Ref: E-066-2013/0 | Updated: Mar 9, 2017
CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis
Ref: E-112-2016/0 | Updated: Mar 1, 2017
Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
Ref: E-174-2016/0 | Updated: Mar 1, 2017
Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Ref: E-136-2013/0 | Updated: Mar 1, 2017
Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Ref: E-006-2017/0 | Updated: Mar 1, 2017
A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening
Ref: E-270-2016/0 | Updated: Feb 28, 2017
Zika Virus Vaccines
Ref: E-181-2016/0 | Updated: Feb 28, 2017
Monoclonal Antibodies that Neutralize Norovirus
Ref: E-226-2011/0 | Updated: Jan 26, 2017
Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
Ref: E-195-2014/0 | Updated: Dec 1, 2016
Use of Roseomonas Species to Treat Eczematous (Atopic Dermatitis) Skin Disease
Ref: E-099-2016-0 | Updated: Oct 27, 2016
Detection and Discrimination of Classical and Atypical L-Type BSE Strains by RT-QuIC
Ref: E-048-2015/0 | Updated: Sep 23, 2015
Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2
Ref: E-141-2015/0 | Updated: Aug 10, 2015
Adaptor for Suspending a Cryovial Over a Centrifuge Tube
Ref: E-080-2015/0 | Updated: Jul 1, 2015
Recombinant Paramyxoviruses Expressing Optimized Heterologous Antigens
Ref: E-241-2014/0 | Updated: Jun 27, 2017
Live Attenuated Japanese Encephalitis Virus Vaccine
Ref: E-231-2014/0 | Updated: Jul 1, 2015
CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells
Ref: E-173-2014/0 | Updated: Jul 1, 2015
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Ref: E-070-2014/0 | Updated: Mar 22, 2016
A Novel Virus-Based Expression System
Ref: E-181-2014/0 | Updated: Aug 18, 2015
The Use of Chimeric Antigen Receptor to Control HIV Infection
Ref: E-212-2014/0 | Updated: Sep 9, 2015
A Novel Fusion Protein for Inhibiting HIV Budding
Ref: E-223-2014/0 | Updated: Sep 9, 2015
Novel Epstein-Barr Virus Vaccines
Ref: E-531-2013/0 | Updated: Dec 17, 2015
Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning
Ref: E-449-2013/0 | Updated: Feb 13, 2017
Multi-specific Chimeric Antigen Receptors Against HIV
Ref: E-170-2013/0 | Updated: Oct 23, 2017
Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein
Ref: E-067-2012/0 | Updated: Apr 15, 2014
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
Ref: E-081-2013/0 | Updated: Feb 11, 2016
Bispecific Antibodies to Target Latent HIV-1 Infection
Ref: E-071-2012/0 | Updated: Jan 6, 2014
Recombinant NIE Antigen from Strongyloides stercoralis
Ref: E-081-2012/0 | Updated: Nov 13, 2013
Vaccine Adjuvant for Inducing Th17 Focused Response
Ref: E-089-2012/0 | Updated: Aug 22, 2013
Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling
Ref: E-527-2013/0 | Updated: Aug 22, 2013
Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection
Ref: E-217-2004/0 | Updated: Jul 9, 2013
Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization
Ref: E-080-2013-0 | Updated: Jun 6, 2013
Novel Vaccine for Prevention and Treatment of Chlamydia Infection
Ref: E-133-2012/0 | Updated: Aug 11, 2015
Transmission-Blocking Malaria Vaccine
Ref: E-222-2012/0 | Updated: Jan 11, 2013
Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders
Ref: E-229-2003/2 | Updated: Nov 16, 2012
Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets
Ref: E-145-2011/0 | Updated: Jul 28, 2016
A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases
Ref: E-279-2011/0 | Updated: Sep 9, 2015
Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine
Ref: E-293-2011/0 | Updated: Apr 11, 2016
Salen-Manganese Compounds for Therapy of Viral Infections
Ref: E-281-2011/0 | Updated: Apr 11, 2016
Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains
Ref: E-253-2011/0 | Updated: Jun 18, 2014
Treatment of Tuberculosis — Adjuvant Therapies to Increase the Efficiency of Antibiotics
Ref: E-189-2011/0 | Updated: May 12, 2016
Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities
Ref: E-202-2011/0 | Updated: Feb 25, 2015
Infectious Hepatitis E Virus Genotype 3 Recombinants – Prospective Vaccine Candidates and Vector System
Ref: E-074-2011/2 | Updated: Mar 22, 2016
Diagnostic Assays and Methods of Use for Detection of Filarial Infection
Ref: E-281-2010/0 | Updated: Sep 23, 2015
Rapid Molecular Assays for Specific Detection and Quantitation of Loa Loa Microfilaremia
Ref: E-014-2011/0 | Updated: May 3, 2016
Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV)
Ref: E-231-2011/0 | Updated: Sep 29, 2011
Monoclonal Antibodies Against Poliovirus
Ref: E-076-2011/0 | Updated: Mar 9, 2015
Multivalent Vaccines for Rabies Virus and Filoviruses
Ref: E-032-2011/0 | Updated: Jul 26, 2011
Mouse IL-12p40 Expressing Cell Line
Ref: E-247-2010/0 | Updated: May 20, 2011
Improved Standard for Immune System Recovery Assay
Ref: E-067-2011/0 | Updated: Nov 3, 2017
Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies
Ref: E-198-2009/0 | Updated: Oct 12, 2010
Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases
Ref: E-184-2010/0 | Updated: Mar 18, 2015
Full-Length Infectious cDNA Clones of Tick Borne Flavivirus
Ref: E-281-1998/0 | Updated: Sep 28, 2010
Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation
Ref: E-055-2009/0 | Updated: Sep 21, 2015
The Use of Recombinant Cholera Toxin-B for the Treatment of Inflammatory Bowel Disease
Ref: E-263-1999/0 | Updated: Jul 16, 2010
Novel Antigen for Use as Vaccine Against Nematode Infection
Ref: E-084-2010/0 | Updated: Jul 12, 2010
Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings
Ref: E-102-2010/0 | Updated: Jul 31, 2012

Pages

Subscribe to Technologies related to NIAID